Hologic (HOLX)
(Delayed Data from NSDQ)
$77.88 USD
-0.46 (-0.59%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $77.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.88 USD
-0.46 (-0.59%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $77.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum D VGM
Zacks News
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
Gear Up for Hologic (HOLX) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Hologic (HOLX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PacBio's (PACB) Revio System to Boost Novogene's German Lab
by Zacks Equity Research
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Hologic (HOLX) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $78.38, marking a +0.35% move from the previous day.
Boston Scientific (BSX) Banks on Global Expansion, Innovation
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio
by Zacks Equity Research
GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software
by Zacks Equity Research
Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?
by Moumi Mondal
Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.
Hologic (HOLX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $78.46, moving +1.45% from the previous trading session.
Stryker (SYK) Completes Artelon's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
by Zacks Equity Research
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
by Nalak Das
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.
Hologic (HOLX) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Hologic (HOLX) concluded the recent trading session at $74.53, signifying a +0.58% move from its prior day's close.
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
by Moumi Mondal
Hologic's (HOLX) fundamental strength and cheaper valuation make it a great new addition to the portfolio.